



# PEGASUS PHARMACEUTICALS INC:


## THE HEARTVUE 6S SYSTEM PROVIDES AN EFFECTIVE 60 SECOND TEST FOR THE EARLY DETECTION OF HEART DISEASE.



**Healthy Heart**



**Moderately Diseased Heart**



**Severely Diseased Heart**

### PEGASUS MARKET SNAPSHOT

**Pegasus Pharmaceuticals Inc.**  
**Symbol: PGUZ-OTC**  
**Shares Issued & Outstanding:**  
**29,987,993**  
**Approximate Float: 5,000,000**  
**2007 Price Range: .61 - .70**  
**[www.pegasusbiosciences.com](http://www.pegasusbiosciences.com)**

### THE GROUND-BREAKING HEARTVUE 6S SYSTEM WILL BE AN INVALUABLE TESTING DEVICE FOR CARDIOLOGISTS, THE ENTIRE HEALTH CARE & FITNESS INDUSTRIES.

The HeartVue 6S System is an advanced technology for early, non-invasive testing of heart disease (CHD).

The medical device uses only 4 limb wires from the patient's wrists and ankles. Patients are easily tested sitting up, fully clothed. It incorporates proprietary software that converts the electric conductivity of the cardiac tissue into a 3-dimensional, color-coded visual portrait. The device allows testers to observe the condition of the heart muscle as well as the intensity of the heart stress load.

The HeartVue 6S System provides a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally be invisible with standard ECG devices. It depicts a disease or stress level as an image instead of a line drawing electrocardiogram.

The system evaluates the stability of current heart conditions. It has portability and provides a rapid analysis.

The system will dramatically cut the costs associated with the detection of ischemic heart disease.

Pegasus is confident that the HeartVue 6S System will prove to be an invaluable testing device for cardiologists, general practitioners, physicians, clinics, hospitals, the fitness industry, sports teams and emergency facilities.


After several successful clinical trials in the United States, the Company is now moving ahead with an aggressive marketing plan in Europe, where it has received a CE Mark for sales to the EU Market.

The HeartVue 6S System is the result of a joint venture between Pegasus Pharmaceuticals Inc. and Heartview LLC, a Cleveland, Ohio-based company which holds the worldwide patent, manufacturing rights of this innovative heart testing medical device.




An earlier version has been cleared for sale in Europe and there is currently a patent pending for the technology in the United States.

Pegasus Pharmaceuticals Inc. has acquired a majority interest in HeartView LLC.
















**The Mold Remove System after 100 days. No mold growth.**



**After just 14 days into a 30 day test, these three competitive anti-mold products all show significant mold growth**

### **A PROGRESSIVE TIMELINE IN TAKING THE HEARTVUE 6S SYSTEM TO MARKET.**

-  1996 Commencement of a research and development program of the HeartVue Project in Moscow.
-  2001 German Patent granted for the earliest version of the medical device named Cardiovisor 6S System.
-  2003 Approval and certification of the Cardiovisor 6S System in Russia.
-  2003 Successful Clinical Studies of the Cardiovisor 6S System by the Russian Cardiology Research & Production Facility at the Health Ministry of the Russian Federation.
-  2003 Patent Pending Approval granted in the United States.
-  2005 Successful Pilot Study to evaluate the HeartVue 6S System by a major New York institution, the Maimonide Hospital
-  2006 CE Mark granted for approval of sale of the HeartVue 6S System in the European Common Market. Pegasus showcases the system at the Medica 2006 Show, Congress World Forum for Medicine in Dusseldorf, Germany.
-  May, 2007 KLM Airlines evaluates an ongoing cardiovascular testing program utilizing the HeartVue 6S System for its 14,000 employees.
-  June, 2007 Pegasus meets with the FDA as an initial step to obtaining FDA Certification in the United States. The meeting was termed a Pre-Investigative Device Exemption/510K Meeting.
-  June 2007 Harvard University initiates a clinical study of the HeartVue 6S System.
-  July 2007 Pegasus proceeds to establish a sales distributor network in Europe and Asia. Unit sales are recorded in Holland, Hungary, Lithuania and Turkey.

## **MARKETING RIGHTS ACQUIRED TO BIOLOGICAL CONCEPT MOLD REMOVAL SYSTEM**

The battle between man and mold has been waged for hundreds of years, hence the control and elimination of mold has become a multi-billion dollar market worldwide. Molds consist of several types of fungi and they're often referred to as mildew. It grows on surfaces such as carpets, wood, sheetrock, insulation and leather. Toxic black mold can cause severe health problems including allergic reactions, headaches, asthma, skin disease, sinus conditions and many other human diseases that are now being connected to molds.

Pegasus' new product, the Mold Remove System (MRS) is based on a new biological concept which controls the mold spores and prevents growth. It is a multi-component control system which removes black mold infestation, cleans and disinfects surfaces and has long-lasting effects on the prevention of future mold growth with its extremely effective inhibitors. It consists of a unique combination of non-toxic, biodegradable ingredients. Other mold prevention products currently on the market have chemically aggressive, hazardous, harmful compounds which are only temporarily effective. The Company's MRS Product not only cleans and disinfects surfaces.... it also kills all fungi cells and black mold spores while preventing future spore growth. The Company's Mold Remove System is a new generation biological system which is not harmful to humans. It may be used safely in any home, school, hospital or commercial environment without any specific precautions.

In a series of independent laboratory tests, the Company's MRS product outperformed several other leading anti-mold products now sold in the U.S. MRS has shown a unique record of 100% efficiency (0% black mold growth) after 100 days of testing on drywall material. This breakthrough product will open a new era in anti-microbial anti-fungi protection and will provide Pegasus with an incredible marketing opportunity in the years to come. The Company is now applying for a series of patents to protect its intellectual property. Pegasus will launch an integrated marketing campaign in North America and Europe.



**PEGASUS PHARMACEUTICALS INC.**  
INNOVATIONS FOR LIFE

(Symbol: PGUZ-OTC)

Website: [www.pegasusbiosciences.com](http://www.pegasusbiosciences.com)

For corporate information please contact Daniel Kesonen, Chairman & CEO of Pegasus Pharmaceuticals & HeartView LLC  
4400 PGA Blvd., Suite 900, Palm Beach Gardens, FL. 33410 U.S.A. Tel: (561-626-9901 Email: [rlk77@comcast.net](mailto:rlk77@comcast.net)

For investor information, please contact Paul Davey at (778) 389-0915 (Canada) Email: [paul@pegasusbiosciences.com](mailto:paul@pegasusbiosciences.com)